No headlines found.
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Business Wire (Mon, 8-Dec 4:05 PM ET)
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
Business Wire (Mon, 10-Nov 9:00 AM ET)
AbCellera Reports Q3 2025 Business Results
Business Wire (Thu, 6-Nov 4:05 PM ET)
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
Business Wire (Tue, 7-Oct 4:05 PM ET)
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
Business Wire (Mon, 29-Sep 4:05 PM ET)
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Abcellera Biologics - Common Shares trades on the NASDAQ stock market under the symbol ABCL.
As of December 17, 2025, ABCL stock price declined to $3.35 with 3,250,606 million shares trading.
ABCL has a beta of 1.90, meaning it tends to be more sensitive to market movements. ABCL has a correlation of 0.19 to the broad based SPY ETF.
ABCL has a market cap of $1.00 billion. This is considered a Small Cap stock.
Last quarter Abcellera Biologics - Common Shares reported $9 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.02.
In the last 3 years, ABCL traded as high as $11.38 and as low as $1.89.
The top ETF exchange traded funds that ABCL belongs to (by Net Assets): IBB, IDNA, SPDW, GWX, ONEQ.
ABCL has outperformed the market in the last year with a return of +17.1%, while the SPY ETF gained +12.0%. However, in the most recent history, ABCL shares have underperformed the stock market with its stock returning -29.8% in the last 3 month period and -3.2% for the last 2 week period, while SPY has returned +2.2% and -1.3%, respectively.
ABCL support price is $3.32 and resistance is $3.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABCL shares will trade within this expected range on the day.
